Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
CYBX's Cash to Debt is ranked higher than
97% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. CYBX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CYBX' s 10-Year Cash to Debt Range
Min: 0.64  Med: 19.35 Max: 25573
Current: No Debt
0.64
25573
Equity to Asset 0.87
CYBX's Equity to Asset is ranked higher than
90% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. CYBX: 0.87 )
Ranked among companies with meaningful Equity to Asset only.
CYBX' s 10-Year Equity to Asset Range
Min: -0.14  Med: 0.79 Max: 0.94
Current: 0.87
-0.14
0.94
Interest Coverage No Debt
CYBX's Interest Coverage is ranked higher than
94% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. CYBX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CYBX' s 10-Year Interest Coverage Range
Min: 5.59  Med: 658.37 Max: 9999.99
Current: No Debt
5.59
9999.99
F-Score: 5
Z-Score: 25.17
M-Score: -2.83
WACC vs ROIC
10.12%
45.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 29.25
CYBX's Operating margin (%) is ranked higher than
96% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. CYBX: 29.25 )
Ranked among companies with meaningful Operating margin (%) only.
CYBX' s 10-Year Operating margin (%) Range
Min: -814.29  Med: -6.79 Max: 30.81
Current: 29.25
-814.29
30.81
Net-margin (%) 18.88
CYBX's Net-margin (%) is ranked higher than
92% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. CYBX: 18.88 )
Ranked among companies with meaningful Net-margin (%) only.
CYBX' s 10-Year Net-margin (%) Range
Min: -800  Med: -6.38 Max: 46.76
Current: 18.88
-800
46.76
ROE (%) 20.63
CYBX's ROE (%) is ranked higher than
92% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. CYBX: 20.63 )
Ranked among companies with meaningful ROE (%) only.
CYBX' s 10-Year ROE (%) Range
Min: -226.26  Med: 10.02 Max: 581.59
Current: 20.63
-226.26
581.59
ROA (%) 18.40
CYBX's ROA (%) is ranked higher than
97% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: -0.62 vs. CYBX: 18.40 )
Ranked among companies with meaningful ROA (%) only.
CYBX' s 10-Year ROA (%) Range
Min: -158.87  Med: -0.90 Max: 58.59
Current: 18.4
-158.87
58.59
ROC (Joel Greenblatt) (%) 90.27
CYBX's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. CYBX: 90.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYBX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -308.11  Med: 6.74 Max: 122.23
Current: 90.27
-308.11
122.23
Revenue Growth (3Y)(%) 12.40
CYBX's Revenue Growth (3Y)(%) is ranked higher than
80% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. CYBX: 12.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYBX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 1.5  Med: 13.70 Max: 180.6
Current: 12.4
1.5
180.6
EBITDA Growth (3Y)(%) 15.90
CYBX's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 4.00 vs. CYBX: 15.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYBX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -54.6  Med: 1.40 Max: 26.3
Current: 15.9
-54.6
26.3
EPS Growth (3Y)(%) 19.60
CYBX's EPS Growth (3Y)(%) is ranked higher than
70% of the 176 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. CYBX: 19.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CYBX' s 10-Year EPS Growth (3Y)(%) Range
Min: -38.2  Med: -12.10 Max: 19.6
Current: 19.6
-38.2
19.6
» CYBX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

CYBX Guru Trades in Q3 2014

Joel Greenblatt 170,735 sh (+718.83%)
Paul Tudor Jones 15,400 sh (+140.63%)
RS Investment Management 979,879 sh (-4.29%)
Jim Simons 2,271,794 sh (-5.78%)
John Hussman 75,000 sh (-62.50%)
» More
Q4 2014

CYBX Guru Trades in Q4 2014

Chuck Royce 3,600 sh (New)
Joel Greenblatt 364,147 sh (+113.28%)
Paul Tudor Jones 23,684 sh (+53.79%)
Jim Simons 2,256,094 sh (unchged)
RS Investment Management Sold Out
John Hussman Sold Out
Jim Simons 2,256,094 sh (-0.69%)
» More
Q1 2015

CYBX Guru Trades in Q1 2015

John Paulson 1,723,800 sh (New)
Louis Moore Bacon 30,000 sh (New)
Chuck Royce Sold Out
Jim Simons 2,065,194 sh (-8.46%)
Paul Tudor Jones 8,730 sh (-63.14%)
Joel Greenblatt 51,849 sh (-85.76%)
» More
Q2 2015

CYBX Guru Trades in Q2 2015

Joel Greenblatt 265,065 sh (+411.22%)
Jim Simons 2,203,094 sh (+6.68%)
John Paulson 1,723,800 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones 6,449 sh (-26.13%)
» More
» Details

Insider Trades

Latest Guru Trades with CYBX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 31.34
CYBX's P/E(ttm) is ranked lower than
55% of the 154 Companies
in the Global Medical Devices industry.

( Industry Median: 28.00 vs. CYBX: 31.34 )
Ranked among companies with meaningful P/E(ttm) only.
CYBX' s 10-Year P/E(ttm) Range
Min: 6.15  Med: 27.59 Max: 57.9
Current: 31.34
6.15
57.9
Forward P/E 24.81
CYBX's Forward P/E is ranked lower than
58% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 23.15 vs. CYBX: 24.81 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 30.20
CYBX's PE(NRI) is ranked lower than
56% of the 153 Companies
in the Global Medical Devices industry.

( Industry Median: 28.00 vs. CYBX: 30.20 )
Ranked among companies with meaningful PE(NRI) only.
CYBX' s 10-Year PE(NRI) Range
Min: 5.52  Med: 26.73 Max: 57.9
Current: 30.2
5.52
57.9
P/B 5.99
CYBX's P/B is ranked lower than
80% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 3.03 vs. CYBX: 5.99 )
Ranked among companies with meaningful P/B only.
CYBX' s 10-Year P/B Range
Min: 3.92  Med: 6.20 Max: 180.33
Current: 5.99
3.92
180.33
P/S 5.87
CYBX's P/S is ranked lower than
74% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. CYBX: 5.87 )
Ranked among companies with meaningful P/S only.
CYBX' s 10-Year P/S Range
Min: 2.16  Med: 4.78 Max: 10.82
Current: 5.87
2.16
10.82
PFCF 23.95
CYBX's PFCF is ranked higher than
69% of the 118 Companies
in the Global Medical Devices industry.

( Industry Median: 32.61 vs. CYBX: 23.95 )
Ranked among companies with meaningful PFCF only.
CYBX' s 10-Year PFCF Range
Min: 10  Med: 21.25 Max: 50.51
Current: 23.95
10
50.51
POCF 21.94
CYBX's POCF is ranked lower than
53% of the 154 Companies
in the Global Medical Devices industry.

( Industry Median: 21.13 vs. CYBX: 21.94 )
Ranked among companies with meaningful POCF only.
CYBX' s 10-Year POCF Range
Min: 9.56  Med: 17.85 Max: 41.15
Current: 21.94
9.56
41.15
EV-to-EBIT 18.01
CYBX's EV-to-EBIT is ranked higher than
59% of the 160 Companies
in the Global Medical Devices industry.

( Industry Median: 21.01 vs. CYBX: 18.01 )
Ranked among companies with meaningful EV-to-EBIT only.
CYBX' s 10-Year EV-to-EBIT Range
Min: -111  Med: 15.50 Max: 309.6
Current: 18.01
-111
309.6
PEG 1.53
CYBX's PEG is ranked higher than
73% of the 59 Companies
in the Global Medical Devices industry.

( Industry Median: 3.10 vs. CYBX: 1.53 )
Ranked among companies with meaningful PEG only.
CYBX' s 10-Year PEG Range
Min: 0.74  Med: 1.25 Max: 1.85
Current: 1.53
0.74
1.85
Shiller P/E 32.90
CYBX's Shiller P/E is ranked lower than
55% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 30.83 vs. CYBX: 32.90 )
Ranked among companies with meaningful Shiller P/E only.
CYBX' s 10-Year Shiller P/E Range
Min: 26.6  Med: 40.25 Max: 230.77
Current: 32.9
26.6
230.77
Current Ratio 7.26
CYBX's Current Ratio is ranked higher than
89% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. CYBX: 7.26 )
Ranked among companies with meaningful Current Ratio only.
CYBX' s 10-Year Current Ratio Range
Min: 0.81  Med: 5.64 Max: 15.71
Current: 7.26
0.81
15.71
Quick Ratio 6.58
CYBX's Quick Ratio is ranked higher than
88% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. CYBX: 6.58 )
Ranked among companies with meaningful Quick Ratio only.
CYBX' s 10-Year Quick Ratio Range
Min: 0.69  Med: 4.91 Max: 15.35
Current: 6.58
0.69
15.35
Days Inventory 259.13
CYBX's Days Inventory is ranked lower than
80% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 130.22 vs. CYBX: 259.13 )
Ranked among companies with meaningful Days Inventory only.
CYBX' s 10-Year Days Inventory Range
Min: 121.94  Med: 234.80 Max: 3102.5
Current: 259.13
121.94
3102.5
Days Sales Outstanding 66.78
CYBX's Days Sales Outstanding is ranked higher than
60% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 69.40 vs. CYBX: 66.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYBX' s 10-Year Days Sales Outstanding Range
Min: 48.89  Med: 58.14 Max: 144.53
Current: 66.78
48.89
144.53

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.09
CYBX's Price/Net Cash is ranked lower than
55% of the 102 Companies
in the Global Medical Devices industry.

( Industry Median: 12.83 vs. CYBX: 14.09 )
Ranked among companies with meaningful Price/Net Cash only.
CYBX' s 10-Year Price/Net Cash Range
Min: 8.12  Med: 16.89 Max: 136.76
Current: 14.09
8.12
136.76
Price/Net Current Asset Value 8.02
CYBX's Price/Net Current Asset Value is ranked lower than
60% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 6.85 vs. CYBX: 8.02 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CYBX' s 10-Year Price/Net Current Asset Value Range
Min: 3.23  Med: 8.65 Max: 333.33
Current: 8.02
3.23
333.33
Price/Tangible Book 6.19
CYBX's Price/Tangible Book is ranked lower than
66% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 4.09 vs. CYBX: 6.19 )
Ranked among companies with meaningful Price/Tangible Book only.
CYBX' s 10-Year Price/Tangible Book Range
Min: 2.6  Med: 6.72 Max: 178.58
Current: 6.19
2.6
178.58
Price/Projected FCF 1.69
CYBX's Price/Projected FCF is ranked higher than
60% of the 114 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. CYBX: 1.69 )
Ranked among companies with meaningful Price/Projected FCF only.
CYBX' s 10-Year Price/Projected FCF Range
Min: 1.52  Med: 2.46 Max: 93.7
Current: 1.69
1.52
93.7
Price/Median PS Value 1.23
CYBX's Price/Median PS Value is ranked lower than
65% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. CYBX: 1.23 )
Ranked among companies with meaningful Price/Median PS Value only.
CYBX' s 10-Year Price/Median PS Value Range
Min: 0.52  Med: 1.15 Max: 19.91
Current: 1.23
0.52
19.91
Price/Peter Lynch Fair Value 1.63
CYBX's Price/Peter Lynch Fair Value is ranked higher than
73% of the 37 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. CYBX: 1.63 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CYBX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.02  Med: 1.42 Max: 2.79
Current: 1.63
1.02
2.79
Price/Graham Number 2.91
CYBX's Price/Graham Number is ranked lower than
57% of the 136 Companies
in the Global Medical Devices industry.

( Industry Median: 2.22 vs. CYBX: 2.91 )
Ranked among companies with meaningful Price/Graham Number only.
CYBX' s 10-Year Price/Graham Number Range
Min: 1.05  Med: 2.75 Max: 10.89
Current: 2.91
1.05
10.89
Earnings Yield (Greenblatt) (%) 5.53
CYBX's Earnings Yield (Greenblatt) (%) is ranked higher than
79% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 0.40 vs. CYBX: 5.53 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYBX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.3  Med: 5.80 Max: 8.1
Current: 5.53
0.3
8.1
Forward Rate of Return (Yacktman) (%) 22.52
CYBX's Forward Rate of Return (Yacktman) (%) is ranked higher than
92% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 4.59 vs. CYBX: 22.52 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CYBX' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -8  Med: -1.10 Max: 39
Current: 22.52
-8
39

Analyst Estimate

Apr16 Apr17
Revenue(Mil) 327 363
EPS($) 2.69 3.00
EPS without NRI($) 2.69 3.00

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:JC8.Germany,
Cyberonics Inc was incorporated in the state of Delaware in 1987. The Company is a medical device company. It is engaged in the design, development, sale and marketing of implantable medical devices that provide vagus nerve stimulation therapy (VNS Therapy), for the treatment of refractory epilepsy and treatment-resistant depression. The Company's proprietary VNS Therapy System includes: an implantable pulse generator to provide stimulation to the vagus nerve; a lead that conducts current pulses from the pulse generator to the vagus nerve; a surgical instrument to assist with the implant procedure; equipment to enable the treating physician to set the pulse generator stimulation parameters for the patient;instruction manuals; and in the VNS Therapy System, magnets to suspend or induce stimulation manually. The VNS Therapy pulse generator and lead are surgically implanted into patients generally during an outpatient procedure. The battery contained in the generator has a finite life, which varies according to the model as well as the stimulation parameters for each patient. At or near the end of the useful life of a battery, a patient may, with the advice of a physician, choose to implant a new generator, which may be done with or without replacing the original lead. The Company sells the VNS Therapy System to hospitals and ambulatory surgery centers (ASCs) on payment terms that are generally 30 days from the shipment date. The Company's medical devices are subject to regulation by numerous government agencies, including the FDA and comparable foreign agencies.
» More Articles for CYBX

Headlines

Articles On GuruFocus.com
comment on CYBX Feb 24 2013 
comment on CYBX Jan 26 2013 
Cyberonics Inc. (CYBX) President & CEO Daniel Jeffrey Moore sells 44,700 Shares Jan 13 2011 
Cyberonics Inc. (CYBX) VP Finance & CFO Gregory H Browne sells 10,000 Shares Jan 12 2011 
Cyberonics Inc. (CYBX) VP Finance & CFO Gregory H Browne sells 5,000 Shares Dec 08 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Nov 22 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Aug 26 2010 
Cyberonics Inc. Reports Operating Results (10-K) Jun 17 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Feb 18 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Nov 19 2009 

More From Other Websites
3 Reasons Why Cyberonics (CYBX) is a Great Stock to Buy Aug 27 2015
Cyberonics: Overseas Potential Strong, Sorin Merger on Track Aug 26 2015
Cyberonics-Sorin Merger Crosses Hurdle; Awaits Closure Aug 26 2015
How Cyberonics (CYBX) Stock Stands Out in a Strong Industry Aug 26 2015
10-Q for Cyberonics, Inc. Aug 22 2015
Cyberonics (CYBX) in Focus: Stock Jumps 7.2% Aug 21 2015
Edited Transcript of CYBX earnings conference call or presentation 20-Aug-15 1:00pm GMT Aug 20 2015
Cyberonics Inc Earnings Call scheduled for 9:00 am ET today Aug 20 2015
CYBERONICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 20 2015
Cyberonics Reports Fiscal 2016 First Quarter Results Aug 20 2015
Cyberonics and Sorin Provide Merger Update Aug 20 2015
Cyberonics beats Street 1Q forecasts Aug 20 2015
Cyberonics beats Street 1Q forecasts Aug 20 2015
Q1 2016 Cyberonics Inc Earnings Release - Before Market Open Aug 20 2015
Cyberonics and Sorin Provide Merger Update Aug 20 2015
Cyberonics Reports Fiscal 2016 First Quarter Results Aug 20 2015
5 Hated Earnings Stocks You Should Love Aug 18 2015
Cyberonics To Report Fiscal Year 2016 First Quarter Results And Host Webcast And Conference Call On... Aug 06 2015
Cyberonics To Report Fiscal Year 2016 First Quarter Results And Host Webcast And Conference Call On... Aug 06 2015
Sorin Slumps as Milan Court Casts Doubt on Cyberonics Deal Jul 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK